The estimated Net Worth of Geoffrey W Dr Guy is at least $61.8 Milión dollars as of 7 December 2020. Geoffrey Guy owns over 720,000 units of GW Pharmaceuticals stock worth over $334,706 and over the last 6 years he sold GWPH stock worth over $57,545,880. In addition, he makes $3,918,990 as Executive Chairman of the Board at GW Pharmaceuticals.
Geoffrey has made over 8 trades of the GW Pharmaceuticals stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 720,000 units of GWPH stock worth $7,862,400 on 7 December 2020.
The largest trade he's ever made was selling 1,200,000 units of GW Pharmaceuticals stock on 1 March 2019 worth over $17,628,000. On average, Geoffrey trades about 494,832 units every 59 days since 2019. As of 7 December 2020 he still owns at least 4,781,521 units of GW Pharmaceuticals stock.
You can see the complete history of Geoffrey Guy stock trades at the bottom of the page.
Dr. Geoffrey W. Guy serves as Executive Chairman of the Board of the Company. Dr. Guy has extensive experience in medical research and global drug development, has held leadership roles in various biopharmaceutical companies, and provides broad and experienced knowledge of the global pharmaceutical industry as well as extensive scientific expertise. Dr. Guy has over 30 years of experience in medical research and global drug development, previously as founder, chairman and chief executive of Ethical Holdings plc (“Ethical Holdings”), a Nasdaq listed drug delivery company (now Amarin Corporation plc, or Amarin), which he founded in 1985 and led it through its Nasdaq listing in 1993. He also founded Phytopharm plc in 1989, of which he was chairman until 1997. Dr. Guy has been the physician in charge of over 300 clinical studies including first dose in man, pharmacokinetics, pharmacodynamics, dose-ranging, controlled clinical trials and large scale multi-centered studies and clinical surveys. He is also an author on numerous scientific publications and has contributed to six books. Dr. Guy was appointed as Visiting Professor in the School of Science and Medicine at the University of Buckingham in July 2011. He also received the “Deloitte Director of the Year Award in Pharmaceuticals and Healthcare” in 2011. Dr. Guy was appointed Visiting Professor at Westminster University, and awarded Honorary DSc at Reading University in 2016. Dr. Guy is also a Member of the Court of Benefactors of The Royal Society of Medicine and holds a BSc in pharmacology from the University of London, a Bachelor of Medicine, Bachelor of Surgery at St. Bartholomew’s Hospital, a Membership of the Royal Colleges of Surgeons of England, and Licentiate of the Royal College of Physicians, a Licentiate in Medicine and Surgery of the Society of Apothecaries and a Diploma of Pharmaceutical Medicine from the Royal Colleges of Physician.
As the Executive Chairman of the Board of GW Pharmaceuticals, the total compensation of Geoffrey Guy at GW Pharmaceuticals is $3,918,990. There are 1 executives at GW Pharmaceuticals getting paid more, with Justin Gover having the highest compensation of $7,864,300.
Geoffrey Guy is 65, he's been the Executive Chairman of the Board of GW Pharmaceuticals since 1998. There are 1 older and 12 younger executives at GW Pharmaceuticals. The oldest executive at GW Pharmaceuticals is William Waldegrave, 73, who is the Non-Executive Independent Director.
Geoffrey's mailing address filed with the SEC is SOVEREIGN HOUSE, VISION PARK, HISTON, , CAMBRIDGE, X0, CB24 9BZ.
Over the last 6 years, insiders at GW Pharmaceuticals have traded over $60,899,192 worth of GW Pharmaceuticals stock and bought 7,200 units worth $48,960 . The most active insiders traders include Geoffrey W Dr Guy, James Noble a Justin D. Gover. On average, GW Pharmaceuticals executives and independent directors trade stock every 10 days with the average trade being worth of $8,011. The most recent stock trade was executed by Douglas B. Snyder on 6 April 2021, trading 8,400 units of GWPH stock currently worth $152,208.
GW Pharmaceuticals executives and other stock owners filed with the SEC include: